1. PMI will present at the 2025 dbAccess Conference on June 3. 2. The company is focused on a smoke-free future and product diversification. 3. PMI's smoke-free products are in 95 markets, with 38.6 million users. 4. Smoke-free business generated 42% of total net revenues in Q1 2025. 5. PMI invested over $14 billion since 2008 in smoke-free product development.
PMI's strong shift towards smoke-free products aligns with consumer trends. Historical data shows stocks of firms successfully transitioning to health-centric models often see price appreciation.
The article highlights PMI's strategic direction and significant growth metrics that attract investor interest, indicating potential price movements.
The trend towards smoke-free innovations is likely to strengthen over time, fostering sustained growth in PMI's valuation and revenues, akin to historical transitions in the health and wellness sectors.
STAMFORD, CT--(BUSINESS WIRE)--Regulatory News:
Philip Morris International Inc. (PMI) (NYSE: PM) will host a live webcast of the company’s remarks and Q&A session with Emmanuel Babeau, Chief Financial Officer, at the 2025 dbAccess Global Consumer Conference on Tuesday, June 3, 2025, at approximately 11:15 a.m. CET (5:15 a.m. ET). The Webcast and presentation slides will be available at www.pmi.com/2025dbaccess, with a post-event recording of the webcast available for one year at the same site.
The webcast will provide a live stream of the entire PMI session and can also be accessed on mobile devices by downloading PMI’s free Investor Relations Mobile App at www.pmi.com/irapp.
Philip Morris International: A Global Smoke-Free Champion
Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of December 31, 2024, PMI's smoke-free products were available for sale in 95 markets, and PMI estimates they were used by 38.6 million adults around the world. The smoke-free business accounted for 42% of PMI’s first-quarter 2025 total net revenues. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to “PMI”, “we”, “our” and “us” mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.